Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA

• Published in: Molecular and cellular probes 2010-10, Vol.24 (5), p.271-280
• Main Authors: Marzese, Diego M., Gago, Francisco E., Vargas-Roig, Laura M., Roqué, María
• Format: Article
• Language: English
• Subjects: Breast Neoplasms - blood; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cell Line, Tumor; Circulating tumor DNA; DNA Methylation; DNA Probes; DNA, Neoplasm - blood; DNA, Neoplasm - genetics; Epigenetic signature; Female; Genetic Predisposition to Disease - genetics; HeLa Cells; Humans; Invasive breast tumor; Neoplasm Invasiveness; Nucleic Acid Amplification Techniques - methods; Polymerase Chain Reaction - methods; Reproducibility of Results
• ISSN: 0890-8508; 1096-1194
• DOI: 10.1016/j.mcp.2010.05.002

Genetic and epigenetic events play a critical role in the tumorigenic process of breast cancer. The more genes are studied, the more accurate the epigenetic “signature” can be established. The aim of our work has been to apply the technique Methylation-Specific Multiplex Ligation dependent Probe Amplification (MS-MLPA) to study the methylation profile of 26 cancer related gene regions in breast cancers. Secondly, we aimed to establish if the epigenetic “signature” could serve to detect circulating tumor DNA (ctDNA) in breast cancer patients. The MS-MLPA was successfully setup and allowed to establish which regions were preferentially associated with the tumor process. The analysis permitted also to detect significant concurrent methylation between some genes. The detection of ctDNA could be performed by a “double-round” MS-MLPA (drMS-MLPA) approach and nested-Methyl Specific PCR (Nested-MSP). This development is an important novelty and served to detect a small amount of tumor DNA shaded into the blood stream of breast cancer patients. We conclude that MS-MLPA is an excellent assay to analyze the methylation profile of a tumor. The 82 studied samples presented a specific methylation “mark”. These studies serve to enhance the knowledge of the role of epigenetic alterations in breast tumors and can contribute to the development of personalized diagnosis, surveillance and treatment strategies.